Titan Biotech Limited has officially notified BSE regarding the allocation of new ISIN INE150C01029 for its upcoming equity share sub-division. The company informed the exchange on February 10, 2026, about the new identification number that will be effective for the stock split scheduled for February 20, 2026.

Share Sub-Division Details

The equity share sub-division involves converting existing shares with a face value of Rs. 10 into smaller denominations. Under this corporate action, each existing equity share of Rs. 10 will be subdivided into 5 equity shares with a face value of Rs. 2 each.

Depository Confirmations

Both major depositories have confirmed the activation of the new ISIN for the sub-divided shares. National Securities Depository Limited (NSDL) activated the ISIN on February 04, 2026, while Central Depository Services (India) Limited (CDSL) made it live on February 09, 2026.

NSDL Activation Details

CDSL Confirmation

CDSL confirmed the ISIN activation on February 09, 2026, making the new identification number operational in their system for equity shares with Rs. 2 face value following the sub-division.

Corporate Communication

The notification was signed by Charanjit Singh, Company Secretary and Compliance Officer (M.No A12726), on behalf of Titan Biotech Limited. This communication follows the company's earlier letter dated January 02, 2026, which initially informed about the record date for the share sub-division.

The company has provided the ISIN activation letters from both NSDL and CDSL to BSE for reference and record-keeping purposes, ensuring complete transparency in the corporate action process.

Titan Biotech Limited has delivered impressive financial performance in Q3FY26, showcasing strong operational growth and profitability improvements. The company announced its unaudited financial results for the quarter and nine months ended December 31, 2025, at a Board meeting held on February 12, 2026.

Strong Revenue Growth Drives Performance

The company demonstrated robust top-line growth with revenue from operations reaching ₹5,650.57 lakhs in Q3FY26, representing a substantial 47.64% increase from ₹3,827.38 lakhs in Q3FY25. Sequential growth was also positive, with revenue rising 3.96% from ₹5,435.47 lakhs in Q2FY26.

Exceptional Profitability Improvement

Titan Biotech's profitability metrics showed remarkable improvement across all parameters. Net profit after tax more than doubled to ₹786.82 lakhs in Q3FY26 from ₹380.19 lakhs in the corresponding quarter last year, marking a 107.01% year-over-year increase. The profit before tax also witnessed strong growth of 106.89%, rising to ₹1,056.21 lakhs from ₹510.49 lakhs.

Basic earnings per share improved significantly to ₹9.52 from ₹4.60 in Q3FY25, reflecting the enhanced profitability per share. The company maintained healthy profit margins with effective cost management across various expense categories.

Nine-Month Performance Highlights

For the nine-month period ended December 31, 2025, Titan Biotech sustained its growth trajectory with total income of ₹16,066.06 lakhs compared to ₹12,381.33 lakhs in the corresponding period last year. Net profit for the nine months reached ₹2,089.15 lakhs, up from ₹1,450.50 lakhs in the previous year.

Consolidated Results Show Strong Performance

The consolidated financial results, which include associate companies Peptech Biosciences Limited and Titan Media Limited, demonstrated even stronger performance. Consolidated net profit after tax reached ₹852.86 lakhs in Q3FY26, with the company benefiting from ₹66.04 lakhs share in profit from associates.

Consolidated earnings per share stood at ₹10.32 for Q3FY26 compared to ₹5.31 in Q3FY25. For the nine-month period, consolidated net profit was ₹2,315.61 lakhs with earnings per share of ₹28.02.

Regulatory Compliance and Tax Optimization

The company has elected to exercise the option under section 115BAA of the Income Tax Act, 1961, optimizing its tax structure. The unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by the statutory auditors A N S K & Associates.

The Board of Directors meeting commenced at 3:00 PM and concluded at 3:40 PM on February 12, 2026, with the results being made available on both BSE Limited's website and the company's official website at www.titanbiotechltd.com .